HOME >> BIOLOGY >> NEWS
NIAID supports research into etiology of fungal-induced inflammation in chronic sinusitis

ce, associate professor at VBI, will head the work at VBI in collaboration with VBI assistant professor Dharmendar Rathore. Researchers at Mayo, including clinical assistant professor Jens Ponikau, who is now at the University at Buffalo School of Medicine & Biomedical Sciences, and Hirohito Kita, professor of Immunology and the director of the Allergic Diseases Laboratory at Mayo, carried out extensive research at the Mayo Clinic which identified a fungal origin for CS.

Accentia Biopharmaceuticals is commercializing a diagnostic and developing a treatment for CS based on the published technology discovered at the Mayo Clinic. Investigators at Mayo discovered that a ubiquitous, normally innocuous mold, Alternaria, colonizes the mucus of the nose and sinus of virtually everybody, but in patients with CS, this non-invasive mold elicits an eosinophilic inflammatory response characterized by release of eosinophil major basic protein (eMBP) in the mucus, which then damages the mucosal epithelial lining of the nose and sinuses and leads to the inflammatory mucosal changes characteristic of CS.

Dr. Jens Ponikau, Assistant Professor of Clinical Otolaryngology, University at Buffalo, commented: Research supported by the National Institutes of Health had previously shown that CS patients have an exaggerated immune response to certain fungi, specifically Alternaria species. The patients reacted to the fungi with the production of the inflammatory mediators, which are crucial for the inflammation in CS, whereas healthy subjects were not reacting. The renewal of the NIH grant will allow Dr. Kita and Dr. Lawrence to further pinpoint the mechanism by which the fungus causes the inflammation, and specifically what fungal products are involved. Both are important milestones to deepen our understanding about CS, and will help us to better understand the mechanism of action of newer treatment approaches, such as anti-fungal therapy.

As previously an
'"/>

Contact: Janet Vasquez
jvasquez@investorrelationsgroup.com
212-825-3210
The Investor Relations Group
1-Jun-2007


Page: 1 2 3

Related biology news :

1. US government $20M NIAID grant funds Proteome Systems catalytic scavenger compounds
2. ESA open-source software supports Germanys TerraSAR-X
3. National Science Foundation supports UCR study of polar lake life forms
4. Hofmeyr skull supports the Out of Africa theory
5. USC study in Nature Genetics supports a stem cell origin of cancer
6. AIUM supports FDA decision to deny over-the-counter use of handheld doppler fetoscopes
7. Conference supports minority students to pursue biomedical careers
8. Study supports urgent need for worldwide ban on lead-based paint
9. Slow-frozen people? Latest research supports possibility of cryopreservation
10. Award supports Virginia Tech research to reduce vehicle emissions, create biofuel
11. Taxpayer Alliance supports senate bill broadening access to federal research

Post Your Comments:
(Date:7/23/2014)... Chrysomya megacephala is commonly found in dead bodies ... time of death, referred to as the post mortem ... C. megacephala from Tamil Nadu is provided for ... characterization through generation of DNA barcoding. This study, significant ... Biodiversity Data Journal . , Chrysomya megacephala ...
(Date:7/23/2014)... New Rochelle, NY -- The potential for clinical ... for transplant-based therapeutic strategies has previously been hindered ... the development of tumors. The ability to use ... for the treatment of heart disease, specifically acute ... Stem Cells and Development , a peer-reviewed ...
(Date:7/23/2014)... MINNETONKA, Minn. , July 23, 2014 /PRNewswire/ ... technology company specializing in clinical study management systems, ... West , a proven life sciences industry executive ... named Chief Operating Officer (COO).  Clareece will be ... and sales growth, operational efficiency and quality product/service ...
Breaking Biology News(10 mins):Dead body feeding larvae useful in forensic investigations 2MedNet Appoints Clareece West As Chief Operating Officer 2
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... regulated information -- UCB today announced an important advance ... topline results from the latest Phase 3 study ... evaluate the efficacy and safety of brivaracetam ... to placebo, as adjunctive treatment in adult focal ... despite treatment with one or two concomitant antiepileptic ...
(Date:7/23/2014)... 2014  Sofinnova Ventures, a Menlo Park ... of Sofinnova Venture Partners IX, L.P. at the hard ... initial fund target of $425 million. Sofinnova ... Consistent with recent funds, SVP IX will provide capital ... along with select investments in earlier stage opportunities. Investments ...
(Date:7/23/2014)... 2014 OncLive® is pleased to ... joined its Strategic Alliance Partnership program. , ... UNC Lineberger will have the opportunity to work ... its cutting-edge research initiatives, community-directed cancer prevention programs, ... work with OncLive to educate their peers by ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
Cached News: